Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.73 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.73 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.71 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | DHODH | Q02127 | 2/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5725413 | 0.98 | CYP4A11 (0.71) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL24426597 | 0.95 | CYP4A11 (0.76) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL19889923 | 0.94 | CYP4F2 (0.74) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL3012713 | 0.90 | LOXL2 (0.76) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| Hydrochloric Acid SCHEMBL4447485 | 0.89 | LOXL2 (0.73) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL70173 | 0.87 | CYP4F2 (0.83) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL10606812 | 0.86 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL5663990 | 0.86 | CYP4A11 (0.91) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL1792728 | 0.86 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2SLC7A5DHODH | |
| SCHEMBL28280189 | 0.85 | CYP4F2 (0.76) | CYP4A11CYP4F2LOXL2DHODHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415553-A | The thermosetting resin of plasticising and related solidified resin, curing method and the product comprising solidified resin | 马萨诸塞大学 | 2019-03-01 | — | — | CN | claimed |
| CN-109415553-A | The thermosetting resin of plasticising and related solidified resin, curing method and the product comprising solidified resin | 马萨诸塞大学 | 2019-03-01 | — | — | CN | disclosed |
| EP-2590942-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-04 | — | — | EP | disclosed |
| US-9079880-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-20120178752-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
| EP-0946501-B1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER (US) | 2006-05-31 | — | — | EP | disclosed |
| US-6998423-B2 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1409455-B1 | PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2006-01-04 | — | — | EP | disclosed |
| US-6900336-B2 | 8-aza-11-deoxy prostaglandin analogues | SYNTEX (U.S.A.) LLC (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040176461-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC | 2004-09-09 | — | — | US | disclosed |
| US-6649657-B2 | Administering amide to treat osteoporosis | PFIZER INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | SYNTEX (U.S.A.) LLC | 2003-06-26 | — | — | US | disclosed |
| US-20030105092-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLEY Q (US) | 2003-06-05 | — | — | US | disclosed |
| US-6492412-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF SULFONAMIDE OR ALKANOY OR AMIDE DERIVATIVE CONTAINING HETERO OR AROMATIC RINGS TO TREAT OSTEOPOROSIS, OSTEOTOMY, CHILDHOOD IDIOPATHIC BOEN LOSS ETC. | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLY O (US) | 2002-02-07 | — | — | US | disclosed |
| US-6344485-B1 | Method for treating glaucoma | PFIZER INC. | 2002-02-05 | — | — | US | disclosed |
| US-6288120-B1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. | 2001-09-11 | — | — | US | disclosed |
| EP-1000619-A2 | Method for treating glaucoma | Pfizer Products Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176461-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | CYP4A11 742/4885CYP4F2 2453/4885LOXL2 279/4885 |
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | CYP4A11 742/4885CYP4F2 2453/4885LOXL2 279/4885 |
| US-20030105092-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | CYP4A11 742/4885CYP4F2 2453/4885LOXL2 279/4885 |
| US-20120178752-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | CYP4A11 900/4885CYP4F2 2367/4885LOXL2 1649/4885 |
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | PTGER4, FFAR4, PTGER1 | CYP4A11 128/4885CYP4F2 395/4885LOXL2 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.